Ad-hoc
Announcements

Disclosure of an inside information acc. to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)

LR Health & Beauty SE: Potential breach of Leverage Covenant as at 30 September 2025 – Management Board intends to enter into discussions with bondholders of the 2024/2028 bond regarding a precautionary resolution on a waiver of compliance with the Leverage Covenant as at 30 September 2025 and an amendment to the bond terms; adjustment of EBITDA guidance for the financial year 2025. 

Ahlen, 28 August 2025 – The Management Board of LR Health & Beauty SE (“LR” or the “Company”) resolved today to initiate precautionary negotiations with the holders of the 2024/2028 bond (ISIN: NO0013149658) concerning a proposal to amend the bond terms. The background to this decision is a potential breach by the Company of the covenant under Clause 13.2 of the bond terms, pursuant to which the Company must ensure that net debt in relation to EBITDA does not exceed the threshold of 4.50:1 as at 30 September 2025 (“Leverage Covenant”). Clause 13.2.1 (iii) of the bond terms provides that the Leverage Covenant decreases from 4.75:1 to 4.50:1 with effect from 1 July 2025. Based on the valuation and calculation information currently available, though still preliminary in nature, the Management Board assumes that compliance with the Leverage Covenant on the review date of 30 September 2025 is unlikely. This is due to EBITDA developing less favourably than expected, primarily attributable to increased or increasing costs in the areas of marketing and sales.

The Management Board has therefore resolved to enter into precautionary negotiations with the bondholders regarding an amendment to the bond terms – in particular the Leverage Covenant – and, if necessary, to request their consent to a waiver of the Leverage Covenant as at 30 September 2025. Furthermore, the Management Board will in due course provide information on the further course of action concerning the nature and timing of any vote on an amendment to the bond terms.

Furthermore, the Management Board of the Company is adjusting the guidance for the  financial year 2025 published on 25 April 2025. With regard to sales (revenue from goods sold), the Management Board now expects a stable development compared with the previous year. Previously, stable to moderately increasing sales had been forecast. EBITDA for the 2025 financial year is now expected to range between EUR 24.0 million and EUR 27.0 million – whereas the previous guidance anticipated significant EBITDA growth compared with the prior-year figure of EUR 27.3 million. The revision of the guidance is essentially due to increased or increasing costs in the areas of marketing and sales. This trend also continued in July, leading the Management Board to conclude that the previous guidance is unlikely to be achieved through catch-up effects or cost-saving measures.

IR Contact: 
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
phone: +49(0)611 - 205855-23
fax: +49(0)611 - 205855-66
email: burbach@cometis.de

End of inside information

Disclosure of an inside information acc. to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR) 

Change in the Management Board of LR Health & Beauty SE

Ahlen, 21 July 2025 – The Supervisory Board of LR Health & Beauty SE, issuer of the bond (ISIN: NO0013149658, German Securities Code (WKN): A3513A), has decided to appoint Mr. Jörg Körfer to the Management Board with effect from August 1, 2025. At the same time, Dr. Andreas Laabs and Andreas Grootz will leave the Management Board by mutual agreement on 31 July 2025.
 

IR contact:

cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone.: +49(0)611 – 205855-23
Fax: +49(0)611 – 205855-66
E-Mail: burbach@cometis.de


End of inside information

Disclosure of an inside information acc. to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)

Ahlen, 26 November 2024 – In the third quarter of 2024 LR Health & Beauty SE (bond, ISIN NO0013149658) increased sales (revenue from goods sold) by 7.2% to EUR 69.4 million (Q3 2023: EUR 64.7 million). Accordingly, sales in the first nine months of 2024 totaled EUR 212.7 million (9M 2023: EUR 205.6 million). In the third quarter of 2024 EBITDA reported amounted to EUR 7.3 million (Q3 2023: EUR 7.1 million). For the first nine months of 2024 EBITDA reported thus totaled EUR 19.0 million (9M 2023: EUR 22.4 million).  
 
Based on the business results for the first nine months of 2024 and the realignment of the career plan for distributors in the third quarter of 2024, LR Health & Beauty SE is adjusting its forecast for sales and EBITDA reported for the full year 2024. LR Health & Beauty SE is increasing the sales guidance for the 2024 financial year and now expects sales to range in a corridor of EUR 288 million to EUR 292 million. Management originally assumed that sales (revenue from goods sold) would be at the previous year's level (2023: EUR 276.5 million). The company is also adjusting its earnings expectations for 2024 and revising its forecast for EBITDA reported to be in the range of EUR 26 million to EUR 29 million. Originally, management expected a slightly lower to stable EBITDA figure year-on-year (2023: EUR 31.4 million). The underlying reason is that the realignment of the career plan for partners in the third and fourth quarters of 2024 will lead to a significant increase in distributors, which will have a positive impact on sales development. At the same time, the result is burdened by refinancing costs incurred and, above all, by one-off, extraordinary effects in the low single-digit million euro range due to changes to the distributors' career plan.   

IR contact: 
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone.: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-Mail: burbach@cometis.de

End of inside information

NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, CYPRUS, HONG KONG, ITALY, JAPAN, NEW ZEALAND, SOUTH AFRICA, THE UNITED KINGDOM OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ANY FURTHER MEASURES FROM LR GLOBAL HOLDING GMBH, LR HEALTH & BEAUTY SE, PARETO SECURITIES AS, FRANKFURT BRANCH, ARCTIC SECURITIES AS OR ANY OTHER PARTY. 

Disclosure of an inside information acc. to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)

LR GLOBAL HOLDING GMBH GIVES NOTICE OF CONDITIONAL VOLUNTARY TOTAL REDEMPTION OF ITS OUTSTANDING 2021/2025 BONDS AND LR HEALTH & BEAUTY SE ISSUES NEW SENIOR SECURED BONDS OF EUR 130 MILLION 

Ahlen, 19 February 2024 – LR Global Holding GmbH (the “Company”) gives conditional notice of voluntary total redemption of its outstanding EUR 125 million senior secured 2021/2025 bonds with ISIN NO0010894850 (the “Existing Bonds”) in full and announces that the Company’s parent company LR Health & Beauty SE has, following a successfull book building process, placed new senior secured bonds with ISIN NO0013149658 due in 2028 with a nominal amount of EUR 130 million (the ”New Bonds”) and generating proceeds of approximately EUR 125 million. 

A notice of a conditional voluntary total redemption of the Existing Bonds will be sent to Verdipapirsentralen ASA (Euronext Securities Oslo) (“VPS”) for delivery to persons registered in the securities account with VPS as holders of Existing Bonds. 

The redemption is conditional upon successful settlement of the New Bonds and the receipt of the proceeds from the New Bonds by the Company from a designated escrow account prior to the lapse of 7 March 2024 (the “Condition”). Should the Condition not be fulfilled by the lapse of 7 March 2024, the redemption will not occur (unless the Condition has been waived by the Company at its sole discretion) which will, in such case, be communicated by the Company through a subsequent announcement. 

Subject to the fulfilment or waiver of the Condition, the date for redemption is set at 11 March 2024 and the record date for the redemption will be 7 March 2024, i.e. two business days prior to the redemption date. The Existing Bonds will then be redeemed at an amount equal to 101.45 % of the total outstanding nominal amount (i.e., EUR 1,014.50 per Existing Bond) together with any unpaid interest accrued until but excluding the redemption date.

In connection with the redemption, the Existing Bonds will be delisted from Frankfurt Stock Exchange and Nasdaq Stockholm.
The New Bonds will have a term of 4 years and will carry a floating rate coupon of 3 months EURIBOR plus 7.5 % per annum. The Company intends to apply for admission to trading of the Bonds on the Open Market of the Frankfurt Stock Exchange and the corporate bond list of Nasdaq Stockholm. 

This announcement is for information purposes only and is not to be construed as an offer to purchase or sell or a solicitation of an offer to purchase or sell with respect to any securities of the Company or LR Health & Beauty SE.

IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de

This information is information that LR Global Holding GmbH is obliged to make public pursuant to the EU Market Abuse Regulation (EU 596/2014). The information in this publication has been made public through the agency of the responsible person set out above for publication at the time stated by the Company's news distributor, EQS Group AG, at the time of publication.

Important Note
THE SECURITIES MENTIONED HEREIN HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE US SECURITIES ACT. THEY MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT. NO PUBLIC OFFERING WILL BE MADE IN THE UNITED STATES AND THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER TO SELL NOR A SOLICITATION TO BUY OR SUBSCRIBE FOR SECURITIES OF LR GLOBAL HOLDING GMBH AND/OR LR HEALTH & BEAUTY SE AND NO EXCHANGE OFFER IS BEING MADE IN THE UNITED STATES, AUSTRALIA, CANADA, CYPRUS, HONG KONG, ITALY, JAPAN, NEW ZEALAND, SOUTH AFRICA, THE UNITED KINGDOM OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION/SUCH OFFER WOULD REQUIRE ANY FURTHER MEASURES FROM LR GLOBAL HOLDING GMBH, LR HEALTH & BEAUTY SE, PARETO SECURITIES AS, FRANKFURT BRANCH, ARCTIC SECURITIES AS OR ANY OTHER PARTY OR BE PROHIBITED BY APPLICABLE LAW.
 

NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, CYPRUS, HONG KONG, ITALY, JAPAN, NEW ZEALAND, SOUTH AFRICA, THE UNITED KINGDOM OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ANY FURTHER MEASURES FROM LR GLOBAL HOLDING GMBH, LR HEALTH & BEAUTY SE, PARETO SECURITIES AS, FRANKFURT BRANCH, ARCTIC SECURITIES AS OR ANY OTHER PARTY. 

Disclosure of an inside information acc. to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)

LR GLOBAL HOLDING GMBH ANNOUNCES ITS INTENTION TO EXERCISE THE CALL-OPTION TO REDEEM ITS OUTSTANDING 2021/2025 BONDS SUBJECT TO A SENIOR SECURED BOND ISSUANCE BY LR HEALTH & BEAUTY SE WITH A TARGET VOLUME OF EUR 125 MILLION 

Ahlen, 13 February 2024 – LR Global Holding GmbH (the “Company”) announces that the Company contemplates a refinancing of the Company’s outstanding EUR 125,000,000 senior secured 2021/2025 bonds with ISIN NO0010894850 (the “Existing Bonds”), subject to an issue of a new senior secured corporate bond under Swedish law (Nordic Bond) with a target volume of EUR 125,000,000 (the ”New Bonds”) by the Company’s parent company LR Health & Beauty SE. 

LR Health & Beauty SE has mandated Pareto Securities AS, Frankfurt Branch and Arctic Securities AS as joint bookrunners to arrange credit investor meetings in connection with the issue of the New Bonds. A capital markets transaction may follow, subject to market conditions. 

Subject to the successful issuance of the New Bonds and the receipt of the required net proceeds from such issuance, the Company intends to mainly use these proceeds to exercise its call-option and redeem in full the EUR 125,000,000 outstanding amount of its Existing Bonds. In accordance with the terms and conditions, the Existing Bonds due 2025 would be redeemed at a redemption price of 101.45 %, plus accrued and unpaid interest thereon up to, but excluding, the redemption date. 

This announcement is not a redemption notice in accordance with the terms and conditions of the Existing Bonds, and such redemption notice will be given by the Company only upon a successful placement of the New Bonds on the basis of a book-building process. 

IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de 

This information is information that LR Global Holding GmbH is obliged to make public pursuant to the EU Market Abuse Regulation (EU 596/2014). The information in this publication has been made public through the agency of the responsible person set out above for publication at the time stated by the Company's news distributor, EQS Group AG, at the time of publication.

Important Note
THE SECURITIES MENTIONED HEREIN HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE US SECURITIES ACT. THEY MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT. NO PUBLIC OFFERING WILL BE MADE IN THE UNITED STATES AND THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER TO SELL NOR A SOLICITATION TO BUY OR SUBSCRIBE FOR SECURITIES OF LR GLOBAL HOLDING GMBH AND/OR LR HEALTH & BEAUTY SE AND NO EXCHANGE OFFER IS BEING MADE IN THE UNITED STATES, AUSTRALIA, CANADA, CYPRUS, HONG KONG, ITALY, JAPAN, NEW ZEALAND, SOUTH AFRICA, THE UNITED KINGDOM OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION/SUCH OFFER WOULD REQUIRE ANY FURTHER MEASURES FROM LR GLOBAL HOLDING GMBH, LR HEALTH & BEAUTY SE, PARETO SECURITIES AS, FRANKFURT BRANCH, ARCTIC SECURITIES AS OR ANY OTHER PARTY OR BE PROHIBITED BY APPLICABLE LAW.
 

Disclosure of an inside information acc. to Article 17 of the Regulation (EU) No 596/2014

Dr. Andreas Laabs becomes new chairman of the management board of the LR Group as successor for Andreas Friesch

Ahlen, 23 May 2022 – LR Global Holding GmbH ("Company") as the issuer of the bonds (WKN: A3H3FM / ISIN: NO0010894850) informs about the fact that Dr. Andeas Laabs, currently CFO and COO of the Company, will become the new chairman of the management board of LR Health & Beauty SE as well as CEO of the Company. The current chairman of the management board, Andreas Friesch, will for personal reasons by mutual agreement resign as chairman of the management board of LR Health& Beauty SE as well as managing director/CEO of the Company and will leave the LR Group on 27 May 2022.

IR Contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Building D
65195 Wiesbaden
Tel.: +49 (0)611 - 205855-23
Fax: +49 (0)611 - 205855-66
E-Mail: burbach@cometis.de

Disclosure of an inside information acc. to Article 17 of the Regulation (EU) No 596/2014

Aloco Holding S.à r.l. contributes shareholder loan to LR Global Holding GmbH

Ahlen, 30 November 2021 – LR Global Holding GmbH (the "Company") as the issuer of the bonds (WKN: A3H3FM / ISIN: NO0010894850) (the "Bonds") informs about the fact that Aloco Holding S.à r.l., the sole shareholder of LR Global Holding GmbH, is expected in the course of today to contribute a shareholder loan in the amount of EUR 146,324,810.00 (principal amount, interest and costs) (the "Shareholder Loan") as a contribution – under corresponding instruction of the management of the company – to the free capital reserve of the Company pursuant to sec. 272 para 2 no. 4 of the German Commercial Code (Handelsgesetzbuch) and to assign the full amount to the Company in order to improve the Company's equity structure.

The Shareholder Loan (with qualified subordination (qualifiziertem Rangrücktritt)) was originally granted on 4 March 2013 in the amount of EUR 109,930,000.00 and bears an interest rate of 0.5% p.a., whereby the repayment (including interest payments) is contractually excluded until all liabilities under the Bonds due 3 February 2025 have been settled in full.

IR Contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Building D
65195 Wiesbaden
Tel.: +49 (0)611 - 205855-23
Fax: +49 (0)611 - 205855-66
E-Mail: burbach@cometis.de